TMCnet News
Research and Markets: MedImmune's Mavrilimumab (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023Research and Markets (http://www.researchandmarkets.com/research/lv9gmc/mavrilimumab) has announced the addition of the "Mavrilimumab (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023" report to their offering. Mavrilimumab, also known as CAM3001, is in Phase IIb of development for RA by MedImmune, a subsidiary of AstraZeneca. It is a human mAb targeted against the alpha subunit of the GM-CSF receptor. GM-CSF levels are elevated in the serum, synovial fluid, and synoviocytes of patients with RA. Inhibition of GM-CSF activity is proposed to reduce the activation, differentiation, and recruitment of macrophages and neutrophils in the damaged and inflamed joints of RA patients.
- Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Mavrilimumab including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Mavrilimumab for the top 6 countries from 2013 to 2023. - Sales information covered for the US, France, Germany, Italy, Spain and the UK. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 3.1 Etiology and Pathophysiology 3.2 Symptoms 3.4 Quality of Life 4 Disease Management 4.1 Diagnosis and Treatment Overview 4.1.1 Diagnosis 4.1.2 Treatment Guidelines 4.1.3 Leading Prescribed Drugs for the Treatment of RA 4.1.4 Clinical Practice 5 Competitive Assessment 6 Unmet Need and Opportunity 6.1 Overview 6.2 Development of Cost-Effective Therapies 6.3 Biomarkers to Predict Responsiveness to Therapy 6.4 Early Diagnosis of RA 6.5 Personalized Treatment Approach 7 Pipeline Assessment 7.1 Overview 7.2 Promising Drugs in Clinical Development 8 Mavrilimumab 9 Appendix For more information visit http://www.researchandmarkets.com/research/lv9gmc/mavrilimumab |
